Ann: Trading Halt, page-271

Been thinking about the timing of a potential takeover bid. Whilst I agree with another poster that a knockout bid from a potential suitor would be ideal because it would most likely value the company on potential indications rather than a premium of the share price on the day, I'd be surprised if that occurred based on results from one 2591 trial.

Is PMS a good indicator of efficacy in the other indications? I really don't know although I'd imagine if the results were outstanding to the point there was statistical significance borne out of only 20 patients (ie 95% confidence intervals, is that possible?) then that would suggest a promising likelyhood the PMS results could correlate to good results in the other indications. By the same token the trial can show clinical significance not just statistical significance, so good results here may be enough for a potential suitor to strike early and hard.

Undoubtedly the pressure ramps up as more Phase 2 trial results get released (if we make it that far). In less than 7 months from today we will know the results from 2 trials. While I'm not sure if a bid will be made in short order post-PMS trial results, I'd expect the company will be entertaining offers in H2 2024 at the latest.